These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9527776)

  • 21. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial.
    Beytout J; Launay O; Guiso N; Fiquet A; Baudin M; Richard P; Baptiste C; Soubeyrand B
    Hum Vaccin; 2009 May; 5(5):315-21. PubMed ID: 19011374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
    Halperin SA; Smith B; Russell M; Scheifele D; Mills E; Hasselback P; Pim C; Meekison W; Parker R; Lavigne P; Barreto L
    Pediatr Infect Dis J; 2000 Apr; 19(4):276-83. PubMed ID: 10783014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria.
    Hirobe S; Matsuo K; Quan YS; Kamiyama F; Morito H; Asada H; Takaya Y; Mukai Y; Okada N; Nakagawa S
    Vaccine; 2012 Feb; 30(10):1847-54. PubMed ID: 22230592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine.
    Lang J; Attanath P; Quiambao B; Singhasivanon V; Chanthavanich P; Montalban C; Lutsch C; Pepin-Covatta S; Le Mener V; Miranda M; Sabchareon A
    Acta Trop; 1998 Jul; 70(3):317-33. PubMed ID: 9777717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of reconstitution of an Haemophilus influenzae type b-tentanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up.
    Hoppenbrouwers K; Roelants M; Ethevenaux C; Vandermeulen C; Knops J; Desmyter J
    Vaccine; 1999 Jun; 17(20-21):2588-98. PubMed ID: 10418907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of Haemophilus influenzae type b capsular polysaccharide tetanus conjugate vaccine (PRP-T) presented in a dual-chamber syringe with DTP.
    Kanra G; Yurdakök K; Ceyhan M; Ozmert E; Türkay F; Pehlivan T
    Acta Paediatr Jpn; 1997 Dec; 39(6):676-80. PubMed ID: 9447756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific antibody responses to diphtheria/tetanus revaccination in children evaluated for immunodeficiency.
    McCusker C; Somerville W; Grey V; Mazer B
    Ann Allergy Asthma Immunol; 1997 Aug; 79(2):145-50. PubMed ID: 9291419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
    Halperin SA; Smith B; Russell M; Hasselback P; Guasparini R; Skowronski D; Meekison W; Parker R; Lavigne P; Barreto L
    Vaccine; 2000 Jan; 18(14):1312-9. PubMed ID: 10618527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial.
    Zarei S; Jeddi-Tehrani M; Mehdi Akhondi M; Zeraati H; Ferydonfar AA; Nasernia J; Tavangar B; Shokri F
    Hum Vaccin Immunother; 2013 Jun; 9(6):1316-22. PubMed ID: 23442608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Combined vaccine against tetanus, diphtheria and polio. A randomized controlled study of immunogenicity and tolerance].
    Banzhoff A; Donner-Banzhoff N; Schwenke C; Girgsdies OE; Jilg W
    Fortschr Med Orig; 2001 Jan; 118(4):169-72. PubMed ID: 11217682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations.
    Southern J; Gelb D; Andrews N; Waight PA; Morris R; Cartwright K; Miller E
    Hum Vaccin; 2006; 2(6):237-42. PubMed ID: 17102644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.
    Laurichesse H; Zimmermann U; Galtier F; Launay O; Duval X; Richard P; Sadorge C; Soubeyrand B
    Hum Vaccin Immunother; 2012 Dec; 8(12):1875-81. PubMed ID: 23032160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults.
    Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Lee SN; Kang SH; Jeong EJ; Jo YM; Kim WJ
    BMC Infect Dis; 2018 Dec; 18(1):628. PubMed ID: 30518331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.